Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quintiles has entered into a strategic alliance with Movetis for commercialisation of its new product, Resolor (prucalopride), in the UK and Germany.
Subscribe to our email newsletter
As per the alliance, Quintiles is expected to execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is expected to be extended later this year to cover other selected European countries.
Movetis has obtained approval for the commercialisation of Resolor in the European Economic Area, for the symptomatic treatment of chronic constipation for women in whom laxatives fail to provide adequate relief.
Dirk Reyn, CEO of Movetis, said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”